- Home
- GDTC vs ICU Comparison
GDTC vs ICU Comparison
Compare GDTC & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDTC
- ICU
- Stock Information
- Founded
- GDTC 2018
- ICU 2018
- Country
- GDTC Singapore
- ICU United States
- Employees
- GDTC N/A
- ICU N/A
- Industry
- GDTC Biotechnology: Pharmaceutical Preparations
- ICU Biotechnology: Pharmaceutical Preparations
- Sector
- GDTC Health Care
- ICU Health Care
- Exchange
- GDTC Nasdaq
- ICU Nasdaq
- Market Cap
- GDTC 21.5M
- ICU 25.6M
- IPO Year
- GDTC 2023
- ICU N/A
- Fundamental
- Price
- GDTC $2.17
- ICU $0.65
- Analyst Decision
- GDTC Buy
- ICU
- Analyst Count
- GDTC 1
- ICU 0
- Target Price
- GDTC $5.00
- ICU N/A
- AVG Volume (30 Days)
- GDTC 21.1K
- ICU 3.8M
- Earning Date
- GDTC 01-01-0001
- ICU 11-12-2025
- Dividend Yield
- GDTC N/A
- ICU N/A
- EPS Growth
- GDTC N/A
- ICU N/A
- EPS
- GDTC N/A
- ICU N/A
- Revenue
- GDTC $573,193.00
- ICU $766,000.00
- Revenue This Year
- GDTC $5.37
- ICU $820.00
- Revenue Next Year
- GDTC N/A
- ICU $63.37
- P/E Ratio
- GDTC N/A
- ICU N/A
- Revenue Growth
- GDTC 63.03
- ICU N/A
- 52 Week Low
- GDTC $1.65
- ICU $0.31
- 52 Week High
- GDTC $4.05
- ICU $4.28
- Technical
- Relative Strength Index (RSI)
- GDTC 62.97
- ICU 42.56
- Support Level
- GDTC $1.95
- ICU $0.62
- Resistance Level
- GDTC $2.30
- ICU $0.72
- Average True Range (ATR)
- GDTC 0.09
- ICU 0.09
- MACD
- GDTC 0.01
- ICU -0.03
- Stochastic Oscillator
- GDTC 70.29
- ICU 14.93
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.